Creative Planning’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25M Buy
397,852
+79,480
+25% +$6.36M 0.02% 357
2025
Q4
$30.4M Sell
318,372
-11,112
-3% -$1.09M 0.02% 290
2025
Q3
$32.2M Buy
329,484
+55,800
+20% +$5.78M 0.02% 261
2025
Q2
$29.4M Buy
273,684
+15,673
+6% +$1.59M 0.03% 254
2025
Q1
$26M Buy
258,011
+37,383
+17% +$3.76M 0.02% 264
2024
Q4
$19.7M Buy
220,628
+16,420
+8% +$1.45M 0.02% 301
2024
Q3
$17.1M Buy
204,208
+14,663
+8% +$1.16M 0.02% 311
2024
Q2
$14.6M Buy
189,545
+22,901
+14% +$1.68M 0.02% 322
2024
Q1
$11.4M Buy
166,644
+15,113
+10% +$972K 0.01% 376
2023
Q4
$8.76M Sell
151,531
-3,571
-2% -$191K 0.02% 410
2023
Q3
$8.19M Sell
155,102
-1,699
-1% -$89.1K 0.01% 404
2023
Q2
$8.48M Buy
156,801
+15,406
+11% +$805K 0.01% 384
2023
Q1
$7.07M Buy
141,395
+4,052
+3% +$191K 0.01% 410
2022
Q4
$6.35M Buy
137,343
+10,735
+8% +$465K 0.01% 428
2022
Q3
$4.9M Sell
126,608
-29,196
-19% -$1.17M 0.01% 443
2022
Q2
$5.81M Buy
155,804
+2,075
+1% +$84.5K 0.01% 419
2022
Q1
$6.81M Buy
153,729
+74,812
+95% +$3.24M 0.01% 384
2021
Q4
$3.35M Buy
78,917
+2,802
+4% +$118K 0.01% 530
2021
Q3
$3.3M Buy
76,115
+5,294
+7% +$234K 0.01% 532
2021
Q2
$3.03M Sell
70,821
-2,221
-3% -$93.4K 0.01% 542
2021
Q1
$2.82M Buy
73,042
+7,888
+12% +$299K 0.01% 589
2020
Q4
$2.34M Sell
65,154
-1,164
-2% -$42K 0.01% 607
2020
Q3
$2.53M Buy
66,318
+4,127
+7% +$159K 0.01% 482
2020
Q2
$2.18M Sell
62,191
-1,923
-3% -$69.3K 0.01% 470
2020
Q1
$2.09M Sell
64,114
-1,751
-3% -$68.4K 0.01% 421
2019
Q4
$2.98M Buy
65,865
+2,199
+3% +$92K 0.01% 397
2019
Q3
$2.59M Buy
63,666
+1,296
+2% +$54.9K 0.01% 426
2019
Q2
$2.68M Buy
62,370
+10,770
+21% +$414K 0.01% 415
2019
Q1
$1.98M Buy
51,600
+1,048
+2% +$40K 0.01% 463
2018
Q4
$1.79M Buy
50,552
+1,505
+3% +$54.6K 0.01% 447
2018
Q3
$1.89M Buy
49,047
+50
+0.1% +$1.75K 0.01% 496
2018
Q2
$1.6M Buy
48,997
+5,390
+12% +$163K 0.01% 534
2018
Q1
$1.19M Sell
43,607
-1,535
-3% -$41.7K ﹤0.01% 647
2017
Q4
$1.12M Buy
45,142
+1,146
+3% +$31.6K ﹤0.01% 678
2017
Q3
$1.28M Buy
43,996
+1,456
+3% +$40.2K 0.01% 605
2017
Q2
$1.18M Buy
42,540
+2,234
+6% +$59.3K 0.01% 613
2017
Q1
$1M Sell
40,306
-759
-2% -$18.5K 0.01% 672
2016
Q4
$888K Buy
41,065
+340
+0.8% +$7.42K 0.01% 675
2016
Q3
$969K Buy
40,725
+17,444
+75% +$416K 0.01% 605
2016
Q2
$544K Sell
23,281
-78
-0.3% -$1.69K ﹤0.01% 732
2016
Q1
$439K Sell
23,359
-14,141
-38% -$248K ﹤0.01% 808
2015
Q4
$692K Buy
37,500
+14,404
+62% +$258K 0.01% 622
2015
Q3
$379K Buy
23,096
+1,998
+9% +$34.2K ﹤0.01% 858
2015
Q2
$373K Buy
21,098
+3,605
+21% +$64.4K ﹤0.01% 741
2015
Q1
$311K Sell
17,493
-2,488
-12% -$39.3K ﹤0.01% 973
2014
Q4
$265K Sell
19,981
-11
-0.1% -$141 ﹤0.01% 993
2014
Q3
$236K Sell
19,992
-585
-3% -$7.37K ﹤0.01% 978
2014
Q2
$263K Buy
20,577
+7,903
+62% +$103K ﹤0.01% 902
2014
Q1
$171K Buy
12,674
+1,934
+18% +$25.4K ﹤0.01% 1075
2013
Q4
$129K Sell
10,740
-232
-2% -$2.74K ﹤0.01% 1061
2013
Q3
$129K Buy
10,972
+320
+3% +$3.46K ﹤0.01% 967
2013
Q2
$99K Buy
+10,652
New +$90.4K ﹤0.01% 995

Other funds holding BSX

Creative Planning's BSX Position: Q1 2026 in Review

Creative Planning increased its Boston Scientific (BSX) stake by 25% in Q1 2026, buying an estimated $6.36M and bringing the position to 397,852 shares worth $25M. The position accounts for 0.02% of the portfolio, ranked #357.

Creative Planning first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $32.2M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Creative Planning held 397,852 shares of Boston Scientific worth $25M as of Q1 2026.
  • Creative Planning bought 79,480 Boston Scientific shares in Q1 2026, an estimated $6.36M.
  • Boston Scientific made up 0.02% of Creative Planning's portfolio in Q1 2026, its #357 holding.
  • Creative Planning first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Boston Scientific position peaked at $32.2M in Q3 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.